The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background
Stereotactic body radiotherapy (SBRT) is gaining wider adoption for prostate cancer management but there remain significant toxicity risks when delivering prostate SBRT with standard techniques. Magnetic resonance‐guided daily adaptive SBRT (MRg‐A‐SBRT) offers technological advantages in precision of radiation dose delivery, but the toxicity profile associated with MRg‐A‐SBRT compared...
BACKGROUND
Although both PSA nadir (PSAn) and testosterone levels at PSA failure are known prognostic factors in men undergoing radiation therapy (RT) and androgen deprivation therapy (ADT) for unfavorable‐risk prostate cancer (PC), it is unclear whether their prognostic significance is independent or overlapping.
METHODS
Seventy‐five men treated with RT with or without 6 months of ADT for unfavorable‐risk...
Background
Defining workup beyond usual clinical practice that may improve treatment outcomes in men with a prostate‐specific antigen (PSA) level of ≤4 ng/mL (vs >4 ng/mL) and Gleason score (GS) 9 to 10 prostate cancer (PC) remains to be determined.
Methods
Between February 25, 1992, and February 25, 2016, 17,632 men with clinical T1‐4 PC with a biopsy GS of 6 to 10 underwent radical prostatectomy...
BACKGROUND
Herein, the authors evaluated how the time to testosterone rebound (TTR) after radiotherapy (RT) and 6 months of androgen deprivation therapy (ADT) impacted the risk of prostate cancer–specific mortality (PCSM) and cardiovascular‐specific mortality (CVM) among men with varying comorbidity extent.
METHODS
Between 1995 and 2001, a total of 206 men who were randomized to receive RT either...
BACKGROUND
Low testosterone at the time of diagnosis of prostate cancer has been associated with a worse prognosis. Whether this is true and how to define the best treatment approach at the time of first prostate‐specific antigen (PSA) failure to the authors' knowledge has not been elucidated to date and was studied herein.
METHODS
Between 1995 and 2001, a total of 58 men with unfavorable‐risk...
BACKGROUND
To date, no targeted therapy has been approved for nasopharyngeal carcinoma (NPC), and this underscores the need for an in‐depth understanding of clinically relevant genomic alterations (CRGAs).
METHODS
Comprehensive genomic profiling was performed for 190 NPC patients, including 20 patients with nasopharyngeal adenocarcinoma (NPAC), 62 patients with nasopharyngeal squamous cell carcinoma...
BACKGROUND
Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about the responsiveness of metastatic PCa to androgen‐deprivation therapy (ADT) among races.
METHODS
The Surveillance, Epidemiology, and End Results (SEER) registry was used to identify men who were diagnosed with distant, de novo, metastatic PCa...
BACKGROUND
African American (AA) men are more likely than non‐AA men to have a comorbid illness that could interact with androgen‐deprivation therapy (ADT) and shorten survival. This study assessed the impact that race had on the risk of all‐cause mortality (ACM) and other‐cause mortality (OCM) among men definitively treated for favorable‐risk prostate cancer (PC).
METHODS
Between 1997 and 2013,...
BACKGROUNDRadiotherapy (RT), short‐course androgen deprivation therapy (ADT), and brachytherapy in various combinations are treatment options for patients with intermediate‐risk prostate cancer (PC), but the question of which combination if any is necessary to minimize PC‐specific mortality (PCSM) risk in patients with favorable or unfavorable intermediate‐risk PC is unknown. The authors assessed...
BACKGROUNDAlthough human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma (OPSCC) tends to present at an advanced nodal stage (N stage), the prognosis is generally better than that for HPV‐negative OPSCC. Prior work has demonstrated the increasing incidence of HPV‐related OPSCC in the United States. This study was designed to determine whether the changing epidemiology of OPSCC...
BACKGROUNDRecently, men with intermediate‐risk prostate cancer (PC) were classified into favorable and unfavorable categories; however, whether the risk of PC‐specific mortality (PCSM) among men with high‐risk PC versus unfavorable intermediate‐risk PC is increased is unknown.
METHODSIn a prospective, randomized trial conducted between 1995 and 2001, 206 men with intermediate‐risk or high‐risk PC...
BACKGROUNDTo the authors' knowledge, it remains unknown whether race‐based differences in cancer outcomes have changed with time. In the current study, the authors assessed whether racial disparities in cancer‐specific mortality have improved over the last 20 years.
METHODSThe Surveillance, Epidemiology, and End Results program was used to identify 2,713,474 patients diagnosed between 1988 and 2007...
BACKGROUNDPredicting life expectancy (LE) in patients with metastatic cancer who are receiving palliative therapies is a difficult task. The purpose of the current study was to develop a LE prediction model among patients receiving palliative radiotherapy (RT) that identifies those patients with short (< 3 months) and long (> 1 year) LEs.
METHODSThe records of 862 patients with metastatic cancer...
BACKGROUNDOptimal management remains unknown following prostate‐specific antigen (PSA) failure when considering comorbidity and PSA kinetics at recurrence. In order to define randomized controlled trials (RCTs) that can address this issue, this study examined factors associated with the risk of death following PSA failure.
METHODSOf 206 men randomized to RT with or without 6 months of androgen suppression...
BACKGROUNDFew studies have quantified temporal patterns of cause‐specific mortality in contemporary cohorts of men with early‐stage seminoma. Given that several management strategies can be applied in these patients, each resulting in excellent long‐term survival, it is important to evaluate associated long‐term sequelae. In particular, data describing long‐term risks of cardiovascular disease (CVD)...
BACKGROUND:A survival benefit has been observed with salvage radiation therapy (RT) for prostate‐specific antigen (PSA) failure after radical prostatectomy (RP) in men with rapid rises in PSA doubling time (DT, <6 months). Whether such a benefit exits in men with a protracted PSA rise in DT (≥6 months) is unclear and was examined in the current study.
METHODS:Of 4036 men who underwent RP at Duke...
BACKGROUND:DNA methylation may be used a potential biomarker for detecting cervical cancer. The authors of this report used quantitative methylation analysis of 4 genes in a full spectrum of cervical lesions to test its potential clinical application.
METHODS:This hospital‐based, retrospective, case‐control study was conducted in 185 patients and included patients who had a normal uterine cervix...
BACKGROUND:The risk of prostate cancer‐specific mortality (PCSM) in healthy elderly men may depend on extent of treatment. The authors of this report compared the use of brachytherapy alone with combined brachytherapy, external‐beam radiation to the prostate and seminal vesicles, and androgen‐suppression therapy (CMT) in this population.
METHODS:The study cohort comprised 764 men aged ≥65 years with...
BACKGROUND:This report evaluated whether biochemical recurrence (BCR) as a time‐dependent covariate (t) after radical prostatectomy (RP) for prostate cancer was associated with the risk of death and whether salvage therapy with radiotherapy (RT) and/or hormonal therapy (HT) can lessen this risk
METHODS:This was a retrospective cohort study of 3071 men who underwent RP at Duke University between 1988...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.